Definiens, ACD to develop RNA biomarker assays

Advanced Cell Diagnostics (ACD), and Definiens have partnered to develop image analysis applications that will enable researchers to quantify RNA molecules in routine clinical specimens.

The partnership will build on ACD’s RNAscope platform and add new specialized image analysis solutions that will process and analyze images from RNAscope assays.

ACD’s RNAscope is an RNA in situ hybridization (ISH) method that can detect and quantify any expressed gene at single molecule sensitivity in individual cells in all major biological specimen types, said the Hayward, Calif. based company.

ACD will demonstrate the technology at American Association for Cancer Research (AACR) conference in Orlando, Fla., April 3 to 6.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.